From: 19/07/2014 to: 25/07/2014 11th ESO-ESMO Course on Oncology for Medical Students, Ioannina, Greece                                         From: 20/09/2014 to: 20/09/2014 ESO-TURKECAG Endocrine Gland Cancers Symposium: Essentials of Thyroid Cancer Management, Izmir, Turkey                                         From: 03/10/2014 to: 04/10/2014 Updates in the Management of Melanoma, Bucharest, Romania                                        From: 27/10/2014 to: 29/10/2014 ESO-SEMM Master in Ethical Counseling in Oncology, Milan, Italy                                         From: 04/10/2014 to: 07/10/2014 ESO-ESSO Masterclass in Breast Cancer Surgery, Ermatingen, Switzerland                                         From: 07/03/2015 to: 12/03/2015 ESO Course on Gastrointestinal Cancers, Tbilisi, Georgia                                        From: 04/11/2014 to: 05/11/2014 BCY2 - 2nd Breast Cancer in Young Women Conference, Dublin, Ireland                                         From: 08/11/2014 to: 12/11/2014 3rd ESO-ESTRO Masterclass in Radiation Oncology, Cascais, Portugal                                        From: 28/11/2014 to: 29/11/2014 Molecular Diagnostics, Genomics and Epigenetics in Clinical Oncology, Rome, Italy                                        From: 30/01/2015 to: 02/02/2015 ESO-EAGEN Masterclass in Endoscopy in Gastrointestinal Oncology, Vienna, Austria                                        From: 07/03/2015 to: 12/03/2015 14th ESO-ESMO Masterclass in Clinical Oncology, Ermatingen, Switzerland                                        From: 05/11/2015 to: 07/11/2015 ABC3 - Advanced Breast Cancer Third International Consensus Conference, Lisbon, Portugal

Funding



The European School of Oncology receives the bulk of its funding through permanent and unrestricted grants from private legacies and donations through its two sustaining foundations: the Swiss-based European School of Oncology Foundation and the Italian Fondazione per la Formazione Oncologica. Additional funding sources include royalties, income from conferences, donations from individual supporters, and grants from commercial companies through its Sharing Progress in Cancer Care programme.

ESO’s financial independence gives it a freedom to set its own agenda that is rare among independent providers of oncology education, enabling it to address topics that are of little interest to commercial companies, including surgery and rare cancers (including childhood tumours), and to fund activities in countries and regions with limited economic resources.

   
   
Oncologica  European